Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.
about
Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Integrated in vivo genetic and ...... triple-negative breast cancer.
@en
Integrated in vivo genetic and ...... triple-negative breast cancer.
@nl
type
label
Integrated in vivo genetic and ...... triple-negative breast cancer.
@en
Integrated in vivo genetic and ...... triple-negative breast cancer.
@nl
prefLabel
Integrated in vivo genetic and ...... triple-negative breast cancer.
@en
Integrated in vivo genetic and ...... triple-negative breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Integrated in vivo genetic and ...... triple-negative breast cancer.
@en
P2093
Aida Shahrabi
Cor Lieftink
Daniel S Peeper
Pasi Halonen
Patricia A Possik
Sedef Iskit
P2860
P304
42859-42872
P356
10.18632/ONCOTARGET.10230
P407
P577
2016-06-22T00:00:00Z